<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758797</url>
  </required_header>
  <id_info>
    <org_study_id>STU1213</org_study_id>
    <nct_id>NCT00758797</nct_id>
  </id_info>
  <brief_title>A Novel Treatment for Metastatic Melanoma</brief_title>
  <official_title>In Situ Photoimmunotherapy: A Tumor Directed Treatment for Advanced Melanoma With Cutaneous Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating
      cream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A novel treatment for metastatic melanoma combining a laser and an immune-system stimulating
      cream with or without injection of a substance that makes the tumor more sensitive to the
      laser.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was not renewed during annual Northwestern Cancer Center review.
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability, safety, toxicity, of novel treatment through evaluation of subject response and physician observation of adverse events.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess time to disease progression</measure>
    <time_frame>24 weeks to years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate tumor response by measuring clinically apparent tumors throughout study.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify overall survival in this study population</measure>
    <time_frame>years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Photoimmunotherapy</intervention_name>
    <description>DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 and older

          2. Subjects must have Stage III or IV melanoma with histologically confirmed cutaneous
             metastatic malignant melanoma from any tumor site.

          3. Subjects must have measurable disease. See section 10.2 for the evaluation of
             measurable disease (RECIST).

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          5. Required laboratory parameters (all blood tests must be obtained within 14 days prior
             to the start of the study treatment):

        Platelet count &gt; 40,000 per mm3 Absolute Neutrophil Count (ANC) &gt; 1,500 per mm3

        Exclusion Criteria:

          1. Life expectancy, in the opinion of the investigator of less than 4 months

          2. Known allergy to any drugs used in treatment

          3. Immunosuppression, including HIV positive subjects, use of systemic steroids daily or
             other immunosuppressive medications within 1 month of treatment

          4. Chemotherapy/immunotherapy within 4 weeks of initiation

          5. Local chemotherapy or immunotherapy to target lesions with 4 weeks of initiation

          6. Radiation therapy at the treatment site within 4 weeks of initiation

          7. Uncontrolled brain metastases

          8. History of cutaneous photosensitization or photodermatoses

          9. Non-treated, active cancers other than melanoma and non-melanoma skin cancers.

         10. Active infectious disease requiring antibiotic therapy

         11. Unstable medical illness

         12. Past or present major psychiatric illness

         13. Pregnant or lactating women

         14. End stage renal disease or serum creatinine greater than the upper limit of normal or
             creatinine clearance &lt;50cc/min

         15. Acute hepatitis (any cause)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murad Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine, Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Murad Alam</investigator_full_name>
    <investigator_title>Professor in Dermatology, Otolaryngology - Head and Neck Surgery, and Surgery-Organ Transplantation</investigator_title>
  </responsible_party>
  <keyword>metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Photosensitizing Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

